FemPulse’s CEO Alexandra Haessler said the FemPulse Ring was designed as an “internal wearable” with a “set it and forget it” ...
EndoQuest plans to test its technology on an estimated 50 participants enrolled across five sites in the US. The company’s ...
EndoQuest will commence its PARADIGM clinical trial for endoluminal robotic colorectal surgery at five leading US hospitals ...
FemPulse announced today that it received FDA investigational device exemption (IDE) approval for its overactive bladder (OAB ...
FemPulse™ announced today Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin its EVANESCE II pivotal clinical trial in female patients suffering ...
EndoQuest Robotics announced today that it received FDA investigational device exemption (IDE) for a study of its surgical ...
RapidPulse, Inc. announced FDA approval of an investigational device exemption (IDE) for the company to study the RapidPulse c ...
In January, Endoquest’s system was accepted into the FDA’s Safer Technologies Program for devices expected to improve the safety of available treatment options. Participants in the program benefit ...
Artivion, Inc. announced that the FDA has granted a humanitarian device exemption (HDE) for use of the of the AMDS hybrid ...
Theradaptive earned the FDA's investigational device exemption approval to broaden its clinical research for the OsteoAdapt SP implant, the company said Dec. 10 ...